ORPHA:293978
Deficiency in anterior pituitary function-variable immunodeficiency syndrome
Also known as: DAVID syndrome
Publications
50
47th percentile
Trials
0
Interventional, condition-specific
Researchers
335
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, genetic endocrine disease characterized by the association of common variable immunodeficiency, manifesting with hypogammaglobulinemia and recurrent or severe childhood-onset sinopulmonary infections, followed, possibly many years later, by symptomatic adrenocorticotropic hormone (ACTH) deficiency resulting from anterior pituitary hormone deficiency.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017407
- UMLS:C4751122
Additional Mondo synonyms (1)
David syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
50 matched papers (47 in last 10 years) Source
- Phenotype characterisedPresent
38 HPO annotations (e.g. Recurrent otitis media; Hypoglycemic coma; Recurrent hypoglycemia) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
38
Associated phenotypes · MONDO:0017407
- Recurrent otitis media
- Hypoglycemic coma
- Recurrent hypoglycemia
- Hypotension
- Recurrent upper respiratory tract infections
Showing 5 of 38 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
50
50 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
50 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
47 in the last 10 years · high confidence · 47th percentile (publications denominator)
Phrase hits: 50 · MeSH hits: 0
Who's working on it?
335
Distinct author names in 50 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Brue T6 papers · 2025
Institut National de la Santé et de la Recherche Médicale (INSERM) U1251, Marseille Medical Genetics (MMG), Institut Marseille Maladies Rares (MarMaRa), Aix-Marseille Université, Marseille, France.
Papers in Europe PMC - 02Barlier A4 papers · 2024
Institut National de la Santé et de la Recherche Médicale (INSERM) U1251, Marseille Medical Genetics (MMG), Institut Marseille Maladies Rares (MarMaRa), Aix-Marseille Université, Marseille, France.
Papers in Europe PMC - 03Castinetti F4 papers · 2025
Aix Marseille University, UMR1251, MMG - Marseille Medical Genetics - MarMaRa Institute, Faculty of Medicine, Marseille, France.
Papers in Europe PMC - 04Fauquier T4 papers · 2025
Aix Marseille University, UMR1251, MMG - Marseille Medical Genetics - MarMaRa Institute, Faculty of Medicine, Marseille, France.
Papers in Europe PMC - 05Mac TT4 papers · 2025
Aix Marseille University, UMR1251, MMG - Marseille Medical Genetics - MarMaRa Institute, Faculty of Medicine, Marseille, France.
Papers in Europe PMC - 06Jullien N3 papers · 2024
INP - Institute of Neurophysiopathology, UMR 7051, Faculty of Medicine, Marseille, France.
Papers in Europe PMC - 07Romanet P3 papers · 2024
Aix Marseille University, UMR1251, MMG - Marseille Medical Genetics - MarMaRa Institute, Faculty of Medicine, Marseille, France.
Papers in Europe PMC - 08Abraham RS2 papers · 2025
Nationwide Children's Hospital, Columbus, Ohio. Electronic address: Roshini.Abraham@nationwidechildrens.org.
Papers in Europe PMC - 09Bonomi M2 papers · 2019
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Papers in Europe PMC - 10Fliegauf M2 papers · 2025
Faculty of Medicine, Center for Chronic Immunodeficiency (CCI), Medical Center, University of Freiburg, Freiburg, Germany.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 40 · after dedupe 40 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 40 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (40)
- isrctn·ISRCTN15819396·Recruiting·A Phase I/IIa trial of KJ-103 in solid cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN78380445·Recruiting·A clinical trial testing a new treatment called mRNA-4194 for people with Lynch syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN55506796·Recruiting·Cauda equina syndrome early recognition study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN42617850·Recruiting·Phase III study of revumenib in combination with intensive chemotherapy in newly diagnosed NPM1-mutated AML
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN33793580·Recruiting·18F-LW223: A new tool for detecting inflammation in the body
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN39055102·No longer recruiting·Comparing how liposomal and standard formulas are absorbed in healthy adults
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10232579·Recruiting·A trial to investigate if psilocybin therapy is effective in improving outcomes for people with opioid use disorder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12036374·No longer recruiting·Understanding the role of community pharmacy in the support of people with long COVID
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13332106·Recruiting·ANYSNAKES: a study to assess different antivenoms for the management of snakebites
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13475234·Recruiting·Exacerbation prevention in patients with both chronic obstructive pulmonary disease and obstructive sleep apnoea
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16634513·Recruiting·Impact of a playful family education strategy with information and communication technology on childhood obesity prevention
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17445597·No longer recruiting·Effect of nutrition education, motivational interviewing and exercise intervention on women with metabolic syndrome in Wakiso district
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN71362981·No longer recruiting·A pneumococcal human challenge study in adults aged 50-84 years
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN79155276·No longer recruiting·A study to learn if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26628699·Recruiting·A Phase I/II trial of UCB4594 in participants with advanced cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN86135778·No longer recruiting·Comparative analysis of adult-onset Still's disease (AOSD) treatments
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11916601·No longer recruiting·Study to measure the direct portal vein pressure gradient in patients with liver disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12812346·Recruiting·Study of etoposide carboplatin chemotherapy in combination with pembrolizumab and lenvatinib therapy in advanced high-grade neuroendocrine tumours
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN78953418·No longer recruiting·Therapist-supervised exercise compared to usual care advice after distal radius fractures in people aged 50 years and over
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14003582·Stopped·Juvia being used for irritable bowel syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN53212600·Stopped·Trial to investigate if the addition of two novel immunotherapy agents in combination with a chemotherapy agent can reduce the size of the cancer and how long they can delay the growth of the cancer in patients with metastatic pancreatic cancer.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17814224·No longer recruiting·A study investigating whether sleep can be measured accurately at home in people with early Alzheimer’s disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN76722400·No longer recruiting·Single ascending dose, multiple ascending dose, first-in-human study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of INS-3001
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10603388·No longer recruiting·A study in healthy male volunteers to look at how the test medicine ([14C]-ATH434) is taken up, broken down and removed from the body when taken as a capsule
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN72772236·Recruiting·Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Deficiency in anterior pituitary function-variable immunodeficiency syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Deficiency in anterior pituitary function-variable immunodeficiency syndrome" OR "DAVID syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Deficiency in anterior pituitary function-variable immunodeficiency syndrome" OR "DAVID syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T12:25:52.535Z
